Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-1101 in Advanced Refractory Solid Tumors
NCT04685473Phase 1Completed
- Sponsor
- Taivex Therapeutics
- Start
- Jan 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of T-1101 in solid tumor, sponsored by Taivex Therapeutics. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Jan 2021; status: completed.
02
Drugs
T-1101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04685473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685473.